Compare EDUC & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | NCEL |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 13.2M |
| IPO Year | 1995 | N/A |
| Metric | EDUC | NCEL |
|---|---|---|
| Price | $1.32 | $2.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.1K | 23.1K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $34,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $1.89 |
| 52 Week High | $1.84 | $4.70 |
| Indicator | EDUC | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 55.26 |
| Support Level | $1.32 | $2.44 |
| Resistance Level | $1.36 | $3.19 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 25.00 | 68.57 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.